SMO and basal cell carcinoma: While the contribution of non-canonical signaling in cancer has never been formally investigated, we propose that it may represent a novel therapeutic target for SMO inhibitors like vismodegib and sonidegib, approved for the treatment of advanced and metastatic basal cell carcinoma.